Clinical trials: Blood Disorder
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very…
- Trial name
- NCT00698646
- Testing
- Valsartan + HCTZ, Valsartan, HCTZ
- Where
- 20 sites in United States
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Drug Users
The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID
Screening, diagnosis and treatment of HCV in PWID, should be part of a harm reduction strategy. Treatment of HCV infected PWID should be delivered in a multidisciplinary care setting with services to reduce the risk of…
- Conditions
- Hepatitis C, Drug Users, Harm Reduction, HIV
- Trial name
- NCT02971488
- Testing
- Screening for HCV in PWID and Linkage-To-Care
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Infanta Leonor
PTSD, Hiv
CPT-L to Improve Outcomes for Individuals With HIV and PTSD
This study plans to adapt and examine the acceptability and feasibility of an evidence-based PTSD treatment that has reduced other HIV transmission behavior (e.g., sexual risk), Cognitive Processing Therapy (CPT), at an HIV…
- Trial name
- NCT05275842
- Testing
- Cognitive Processing Therapy- Lifesteps (CPT-L), Lifesteps
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Medical University of South Carolina
Myelodysplastic Syndromes
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
The primary objective of the trial is to assess the activity of the combined use of Valproic Acid (VPA)in combination with 5-Azacytidine (5-Aza C) in the treatment of MDS.
- Trial name
- NCT00439673
- Testing
- 5-Azacytidine, Valproic Acid, ATRA
- Where
- 7 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hypertension
SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
To evaluate the effectiveness of diet management with a losartan based titration regimen versus losartan based titration regimen alone on blood pressure reduction in hypertensive patients.
- Trial name
- NCT00739674
- Testing
- losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]), Low Salt Diet
- Volunteers
- 992 people
- Sponsor
- Organon and Co
Hepatitis C, Chronic
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV)…
- Trial name
- NCT01849562
- Testing
- Sovaprevir, ACH-3102, Ribavirin
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
The purpose of this study is to determine if pregnancy-limited, short-term combination HIV treatment regimens -- which were used solely for the prevention of mother to child transmission of HIV and discontinued postpartum …
- Trial name
- Nearly Naive (NCT00442962)
- Testing
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Where
- 9 sites in United States, Brazil and 1 more
- Volunteers
- 54 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hypertension
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan.
- Trial name
- NCT01307046
- Testing
- MK-0954A, Losartan
- Volunteers
- 336 people
- Sponsor
- Organon and Co
Leukemia
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00562328
- Testing
- Alemtuzumab, Rituximab, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Sickle Cell Disease
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease.
- Trial name
- NCT01794000
- Testing
- Prasugrel
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 341 people
- Sponsor
- Eli Lilly and Company
Neutropenia
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
This study aims to evaluate the pharmacokinetics of posaconazole (POS) administered intravenously (IV) or orally to immunocompromised pediatric participants.
- Trial name
- NCT02452034
- Testing
- Posaconazole IV solution, Posaconazole powder for oral suspension
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short.
- Trial name
- NCT04905407
- Testing
- Tamibarotene, Venetoclax, Azacitidine
- Where
- 28 sites in United States, France
- Volunteers
- 66 people
- Sponsor
- Syros Pharmaceuticals
Non Malignant Disorders, Immunodeficiencies
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients < 21…
- Conditions
- Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies
- Trial name
- NCT00744692
- Testing
- Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Duke University
Craniosynostosis, Bleeding
Tranexamic Acid for Craniofacial Surgery
This is a randomized, blinded, prospective study that will investigate the potential benefit of tranexamic acid to reduce the intraoperative bleeding and blood transfusions in pediatric patients undergoing craniofacial surgeries.
- Trial name
- NCT00722436
- Testing
- Tranexamic acid, saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pittsburgh
Hemophilia A
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII…
- Trial name
- NCT00157157
- Testing
- Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
- Where
- 35 sites in United States, Austria and 8 more
- Volunteers
- 66 people
- Sponsor
- Baxalta now part of Shire
Hepatitis C, Chronic
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
This is a randomized, open-label, multinational study designed to evaluate the "standard" regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily [Arm PEG2b 1.5/R (24 weeks)], compared to a lower…
- Trial name
- NCT00302081
- Testing
- peginterferon alfa-2b (SCH 54031), ribavirin (SCH 18908)
- Volunteers
- 696 people
- Sponsor
- Merck Sharp & Dohme LLC
Spinal Cord Injury
Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury
Following spinal cord injury autonomic regulation of the cardiovascular system is impaired, which results in a variety of measurable abnormalities in blood pressure.
- Trial name
- NCT02307565
- Testing
- Midodrine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Chronic Phase Myelofibrosis, Primary Myelofibrosis
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase (MPN-AP), or blast phase (MF-BP).
- Conditions
- Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Trial name
- NCT03065400
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- John Mascarenhas
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF).
- Trial name
- NCT01384734
- Testing
- BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 254 people
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.